Latest Breaking News On - Lynk pharmaceuticals co ltd - Page 1 : vimarsana.com

Lynk Pharmaceuticals Announced First Rheumatoid Arthritis Patient Dosed in Phase Ⅲ Clinical Study of LNK01001

/PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that it has...

Lynk Pharmaceuticals Announced First Rheumatoid Arthritis Patient Dosed In Phase III Clinical Study Of LNK01001

Lynk Pharmaceuticals Completes Series C2 Financing Round, with Total C Round Funding of 322 Million RMB

LNK01001 Achieves Primary End Point in Phase II Trial for Atopic Dermatitis

Patients given LNK01001 showed significant improvement in Eczema Area and Severity Index scores over placebo.

Lynk Pharmaceuticals Announced Positive Topline Data from Phase II Clinical Trial of LNK01001 in the Treatment of Atopic Dermatitis

Lynk Pharmaceuticals Announces First Atopic Dermatitis Patient Dosed with LNK01004 in Phase Ib Clinical Study

LYNK's LNK01001 Achieved Exciting Phase II Results in Rheumatoid Arthritis

HANGZHOU, China, May 16, 2023 /PRNewswire/ — Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as ‘Lynk Pharmaceuticals’), an innovative clinical...

Lynk Pharmaceuticals Announces the First Participant Dosed in Phase I Trial of LNK01004

/PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that it has...

Lynk Pharmaceuticals and Simcere announced Strategic Commercialization Partnership upon novel JAK1 inhibitor LNK01001

/PRNewswire/ -- On March 18, 2022, Lynk Pharmaceuticals Co., Ltd. (Lynk Pharmaceuticals) and Simcere (2096.HK) announced a strategic partnership to develop and...

Lynk Pharmaceuticals announced the completion of Series B financing of $50 million

/PRNewswire/ -- Lynk Pharmaceuticals CO., LTD (hereinafter referred to as "Lynk Pharmaceuticals"), an innovative pharmaceutical R&D company, today announced...